|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ST20 |
Gene summary for ST20 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ST20 | Gene ID | 400410 |
| Gene name | suppressor of tumorigenicity 20 | |
| Gene Alias | HCCS-1 | |
| Cytomap | 15q25.1 | |
| Gene Type | ncRNA | GO ID | GO:0000737 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 400410 | ST20 | C04 | Human | Oral cavity | OSCC | 3.38e-18 | 5.91e-01 | 0.2633 |
| 400410 | ST20 | C21 | Human | Oral cavity | OSCC | 5.13e-14 | 3.73e-01 | 0.2678 |
| 400410 | ST20 | C30 | Human | Oral cavity | OSCC | 9.34e-46 | 1.31e+00 | 0.3055 |
| 400410 | ST20 | C38 | Human | Oral cavity | OSCC | 7.85e-08 | 5.78e-01 | 0.172 |
| 400410 | ST20 | C43 | Human | Oral cavity | OSCC | 3.84e-18 | 4.16e-01 | 0.1704 |
| 400410 | ST20 | C46 | Human | Oral cavity | OSCC | 1.83e-17 | 3.19e-01 | 0.1673 |
| 400410 | ST20 | C51 | Human | Oral cavity | OSCC | 8.14e-15 | 4.50e-01 | 0.2674 |
| 400410 | ST20 | C57 | Human | Oral cavity | OSCC | 2.01e-02 | 1.29e-01 | 0.1679 |
| 400410 | ST20 | C06 | Human | Oral cavity | OSCC | 3.91e-06 | 8.02e-01 | 0.2699 |
| 400410 | ST20 | C08 | Human | Oral cavity | OSCC | 1.29e-11 | 2.90e-01 | 0.1919 |
| 400410 | ST20 | C09 | Human | Oral cavity | OSCC | 9.81e-05 | 1.67e-01 | 0.1431 |
| 400410 | ST20 | LN22 | Human | Oral cavity | OSCC | 8.56e-05 | 5.61e-01 | 0.1733 |
| 400410 | ST20 | LN46 | Human | Oral cavity | OSCC | 3.95e-02 | 1.97e-01 | 0.1666 |
| 400410 | ST20 | LP17 | Human | Oral cavity | LP | 3.34e-02 | 1.99e-01 | 0.2349 |
| 400410 | ST20 | SYSMH1 | Human | Oral cavity | OSCC | 1.14e-05 | 1.47e-01 | 0.1127 |
| 400410 | ST20 | SYSMH2 | Human | Oral cavity | OSCC | 8.20e-06 | 2.15e-01 | 0.2326 |
| 400410 | ST20 | SYSMH3 | Human | Oral cavity | OSCC | 2.55e-09 | 2.15e-01 | 0.2442 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:002241119 | Oral cavity | OSCC | cellular component disassembly | 283/7305 | 443/18723 | 9.57e-27 | 3.37e-24 | 283 |
| GO:000989620 | Oral cavity | OSCC | positive regulation of catabolic process | 307/7305 | 492/18723 | 2.29e-26 | 7.64e-24 | 307 |
| GO:003133120 | Oral cavity | OSCC | positive regulation of cellular catabolic process | 273/7305 | 427/18723 | 6.39e-26 | 2.02e-23 | 273 |
| GO:004586220 | Oral cavity | OSCC | positive regulation of proteolysis | 236/7305 | 372/18723 | 6.53e-22 | 1.38e-19 | 236 |
| GO:003465517 | Oral cavity | OSCC | nucleobase-containing compound catabolic process | 244/7305 | 407/18723 | 5.38e-18 | 5.49e-16 | 244 |
| GO:200011620 | Oral cavity | OSCC | regulation of cysteine-type endopeptidase activity | 152/7305 | 235/18723 | 1.14e-15 | 8.13e-14 | 152 |
| GO:004670015 | Oral cavity | OSCC | heterocycle catabolic process | 254/7305 | 445/18723 | 5.07e-15 | 3.31e-13 | 254 |
| GO:004328120 | Oral cavity | OSCC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 137/7305 | 209/18723 | 5.94e-15 | 3.80e-13 | 137 |
| GO:004427016 | Oral cavity | OSCC | cellular nitrogen compound catabolic process | 256/7305 | 451/18723 | 9.67e-15 | 5.88e-13 | 256 |
| GO:001943915 | Oral cavity | OSCC | aromatic compound catabolic process | 263/7305 | 467/18723 | 1.49e-14 | 8.84e-13 | 263 |
| GO:001604917 | Oral cavity | OSCC | cell growth | 268/7305 | 482/18723 | 6.55e-14 | 3.51e-12 | 268 |
| GO:190136115 | Oral cavity | OSCC | organic cyclic compound catabolic process | 272/7305 | 495/18723 | 2.73e-13 | 1.36e-11 | 272 |
| GO:005105210 | Oral cavity | OSCC | regulation of DNA metabolic process | 207/7305 | 359/18723 | 4.45e-13 | 2.17e-11 | 207 |
| GO:005254720 | Oral cavity | OSCC | regulation of peptidase activity | 255/7305 | 461/18723 | 5.78e-13 | 2.75e-11 | 255 |
| GO:005105414 | Oral cavity | OSCC | positive regulation of DNA metabolic process | 126/7305 | 201/18723 | 8.12e-12 | 3.01e-10 | 126 |
| GO:00094114 | Oral cavity | OSCC | response to UV | 99/7305 | 149/18723 | 1.01e-11 | 3.70e-10 | 99 |
| GO:000155816 | Oral cavity | OSCC | regulation of cell growth | 228/7305 | 414/18723 | 1.74e-11 | 6.09e-10 | 228 |
| GO:001095220 | Oral cavity | OSCC | positive regulation of peptidase activity | 123/7305 | 197/18723 | 2.12e-11 | 7.21e-10 | 123 |
| GO:005254820 | Oral cavity | OSCC | regulation of endopeptidase activity | 235/7305 | 432/18723 | 4.35e-11 | 1.40e-09 | 235 |
| GO:007121416 | Oral cavity | OSCC | cellular response to abiotic stimulus | 186/7305 | 331/18723 | 1.38e-10 | 4.10e-09 | 186 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ST20 | SNV | Missense_Mutation | novel | c.231N>A | p.Phe77Leu | p.F77L | Q9HBF5 | protein_coding | deleterious_low_confidence(0) | benign(0.007) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ST20 | SNV | Missense_Mutation | c.184G>A | p.Gly62Ser | p.G62S | Q9HBF5 | protein_coding | tolerated_low_confidence(0.21) | benign(0.042) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| ST20 | insertion | In_Frame_Ins | novel | c.98_99insTTATTTAAAAGT | p.Leu33_Glu34insTyrLeuLysVal | p.L33_E34insYLKV | Q9HBF5 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| ST20 | SNV | Missense_Mutation | c.190A>T | p.Ile64Phe | p.I64F | Q9HBF5 | protein_coding | tolerated_low_confidence(0.15) | benign(0.199) | TCGA-AP-A1DR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| ST20 | SNV | Missense_Mutation | novel | c.110N>A | p.Gly37Glu | p.G37E | Q9HBF5 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.767) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| ST20 | SNV | Missense_Mutation | novel | c.162N>T | p.Lys54Asn | p.K54N | Q9HBF5 | protein_coding | deleterious_low_confidence(0.01) | benign(0.242) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ST20 | SNV | Missense_Mutation | novel | c.52G>A | p.Gly18Ser | p.G18S | Q9HBF5 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| ST20 | SNV | Missense_Mutation | c.190N>C | p.Ile64Leu | p.I64L | Q9HBF5 | protein_coding | tolerated_low_confidence(0.64) | benign(0) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ST20 | SNV | Missense_Mutation | novel | c.63N>T | p.Lys21Asn | p.K21N | Q9HBF5 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.782) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| ST20 | SNV | Missense_Mutation | c.184N>A | p.Gly62Ser | p.G62S | Q9HBF5 | protein_coding | tolerated_low_confidence(0.21) | benign(0.042) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |